These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33849729)

  • 41. Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28.
    Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF
    Eur Urol; 2019 Apr; 75(4):e98-e99. PubMed ID: 30503180
    [No Abstract]   [Full Text] [Related]  

  • 42. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Van den Broeck T; Wiegel T;
    Eur Urol; 2020 Sep; 78(3):e120-e121. PubMed ID: 32684306
    [No Abstract]   [Full Text] [Related]  

  • 43. Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Mottet N; Wiegel T
    Eur Urol; 2020 Sep; 78(3):e116-e117. PubMed ID: 32536484
    [No Abstract]   [Full Text] [Related]  

  • 44. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
    Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
    [No Abstract]   [Full Text] [Related]  

  • 45. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Epstein JI; Trock B; Han M
    Eur Urol; 2017 Jul; 72(1):e11-e12. PubMed ID: 28108147
    [No Abstract]   [Full Text] [Related]  

  • 46. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
    Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
    [No Abstract]   [Full Text] [Related]  

  • 47. Reply to Michael Froehner's letter to the editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 2013;64:372-8.
    Nepple KG; Kibel AS
    Eur Urol; 2014 Mar; 65(3):e42. PubMed ID: 24315707
    [No Abstract]   [Full Text] [Related]  

  • 48. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
    Kamran SC; Seisen T; Markt SC; Preston MA; Trinh QD; Frazier LA; Choueiri TK; Martin NE; Nguyen PL; Beard CJ
    Eur Urol; 2018 Apr; 73(4):e96-e97. PubMed ID: 29358058
    [No Abstract]   [Full Text] [Related]  

  • 49. Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2018 Jan; 73(1):e11-e12. PubMed ID: 28801127
    [No Abstract]   [Full Text] [Related]  

  • 50. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
    Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
    [No Abstract]   [Full Text] [Related]  

  • 51. Reply to Kwang Hyun Kim and Koon Ho Rha's letter to the editor Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
    Tosco L; Van den Bergh L; Joniau S
    Eur Urol; 2013 Sep; 64(3):e57-8. PubMed ID: 23769590
    [No Abstract]   [Full Text] [Related]  

  • 52. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.
    Murtola TJ; Syvälä H; Riikonen J
    Eur Urol; 2019 Jun; 75(6):e166-e167. PubMed ID: 30738709
    [No Abstract]   [Full Text] [Related]  

  • 53. Reply to Berardino De Bari, Stefano Arcangeli, and Filippo Alongi's letter to the editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014;65:546-51.
    Suardi N; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):e27-8. PubMed ID: 25281387
    [No Abstract]   [Full Text] [Related]  

  • 54. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 55. Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8.
    Davis ID; Pezaro C; Xie W; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):e177-e178. PubMed ID: 28041718
    [No Abstract]   [Full Text] [Related]  

  • 56. Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
    Becker REN; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Feb; 79(2):e58-e59. PubMed ID: 33218822
    [No Abstract]   [Full Text] [Related]  

  • 57. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
    Gandaglia G; Sun M; Briganti A; Karakiewicz PI
    Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
    [No Abstract]   [Full Text] [Related]  

  • 58. Reply to Stefano C.M. Picozzi, Cristian Ricci and Luca Carmignani's letter to the editor re: Giacomo Novara, Vincenzo Ficarra, Simone Mocellin, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 2012;62:382-404.
    Novara G; Ficarra V
    Eur Urol; 2013 Feb; 63(2):e29-31. PubMed ID: 23218764
    [No Abstract]   [Full Text] [Related]  

  • 59. Reply to Yejinpeng Wang, Yaoyi Xiong, and Xinghuan Wang's Letter to the Editor re: Zhengzheng Xu, Guangzhe Ge, Bao Guan, et al. Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles. Eur Urol 2020;77:288-90.
    Zhengzheng X; Ge G; Guan B; Lei Z; Hao X; Zhou Y; Shi Y; Lu H; Wang J; Peng D; Wu X; He H; Zhang B; Li X; Zhou L; Ci W
    Eur Urol; 2020 Apr; 77(4):e91-e92. PubMed ID: 31892480
    [No Abstract]   [Full Text] [Related]  

  • 60. Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Kearns JT; Newcomb LF; Lin DW
    Eur Urol; 2018 Dec; 74(6):e151. PubMed ID: 30195835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.